The Federal Trade Commission is intensifying its focus on potential anticompetitive conduct in the pharmaceutical industry as a number of high-revenue drugs approach the end of their patent protections, the agency's top antitrust official said on Tuesday.
Dan Guarnera, director of the FTC's bureau of competition, addressed the issue at the Reuters Events' Pharma USA conference in Philadelphia, describing oversight of the market shifts triggered by patent expirations as part of the agency's "laser focus" on healthcare. He emphasized the FTC's interest in ensuring that the market functions as intended once patents lapse.
"We are always happy to hear concerns from market participants, including generics and patient groups to make sure that the entry of generics can happen as it’s designed to under the patent laws," Guarnera said.
He pointed to the timetable for exclusivity losses among several top-selling U.S. medicines, noting that many of these products are projected to lose their patent protection by the end of the decade. Among the drugs named were Keytruda, manufactured by Merck; Eliquis, sold by Bristol Myers Squibb and Pfizer; and Darzalex, produced by Johnson & Johnson.
The FTC has made healthcare an explicit enforcement priority and has actively moved to block transactions it views as anticompetitive. Guarnera cited recent agency actions, including efforts that led to the abandonment on Monday of a $356 million medical equipment merger.
"It’s an area that we care a lot about, not only because of obviously the huge effect it has on the economy, but also because it has such a direct effect on Americans’ pocketbooks and well-being," Guarnera said. He added that he was speaking for himself and that his remarks may not reflect the views of the agency as a whole.
The FTC's interventionist posture was further illustrated by the recent termination of an acquisition effort by Switzerland-based Alcon. The company said on Monday that it had abandoned its bid to buy Lensar after the FTC indicated it intended to sue to block the transaction.
According to the agency, the proposed combination would have reduced competition in the market for laser systems used in a specific form of cataract surgery, potentially increasing prices for those systems and slowing innovation. Guarnera reiterated the agency's concern that such deals could both raise costs and dampen technological progress.
Beyond transactions involving marketed products, the FTC is also attuned to how mergers might influence firms' incentives to invest in research and development. Guarnera said the agency evaluates whether a merger would affect a company's motivation to pursue its R&D programs and to continue developing pipeline drugs.
"We really do care about and want to see the effects of a merger on the firm's incentives to innovate, to continue their research and development programs and continue their pipeline drug production," he said.
This enforcement stance comes at a moment when the expiration of patents on major drugs could reshape competitive dynamics across branded pharmaceuticals, generics, and related medical equipment markets. The FTC's actions highlight the intersection of competition policy, patient costs, and the incentives that drive pharmaceutical innovation.